posted
Aethlon Medical Acquires Strategic Cancer Therapy Patent
Business Wire "US Press Releases "
SAN DIEGO--(BUSINESS WIRE)--
Aethlon Medical, Inc., (OTCBB:AEMD), a pioneer in developing therapeutic devices for infectious disease, announced today that it has acquired world-wide rights to a patent submission entitled, "De-repression of anticancer immunity through extracorporeal removal of microvesicular particles." Under the patent, assigned to Aethlon Medical by London Health Science Center Research Inc., the Aethlon Hemopurifier(TM) would address a significant unmet clinical need in cancer therapy by reducing the presence of tumor-secreted microvesicles that inhibit the immune system from responding in cancer patients.
Microvesicular particles are small enough to be separated from circulation by the Hemopurifier(TM), and they have glycosylated surfaces that are the binding targets of affinity capture agents immobilized in the Hemopurifer(TM) to capture viral pathogens. As such, the Hemopurifer(TM) that has progressed through animal studies, biocompatibility testing, multiple invitro virus studies, and demonstrated safety and virus capture in a human clinical study, may also offer an important clinical benefit to those afflicted with cancer.
At present, Aethlon has submitted a preliminary Investigational Device Exemption with The Food and Drug Administration (FDA) related to the use of the Hemopurifier(TM) in the United States as a broad-spectrum countermeasure against bioweapon threats and naturally evolving pathogens, including virulent influenza. The Company also plans to continue human safety and efficacy testing of the Hemopurifier(TM) in India.
-------------------- Before you criticize someone, try walking a mile in their shoes, then when you do, you'll be a mile away and have their shoes.
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
